

January 05, 2026

To,
National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Sub : Appointment of Mr. Rajdeep Panwar as Chief Commercial Officer

Ref : Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we wish to inform you that the Board of Directors ("Board") of Thyrocare Technologies Limited ("the Company"), upon the recommendation of the Nomination and Remuneration Committee ("NRC"), has approved the appointment of **Mr. Rajdeep Panwar** as **Chief Commercial Officer** of the Company, categorised as **Senior Management Personnel**, with effect from **January 05, 2026**.

The aforesaid appointment was approved by the Board by way of a **resolution passed by circulation on January 05, 2026 at 11:07 A.M. (IST)**.

In compliance with Regulation 30 of the SEBI LODR Regulations read with **SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024**, the requisite disclosure is enclosed as **Annexure – 1**.

The aforesaid disclosures are also being made available on the website of the Company at <https://investor.thyrocare.com/announcements/>.

This is submitted for your information and records.

Yours faithfully,
For **Thyrocare Technologies Limited**

Brijesh Kumar
Company Secretary and Compliance Officer



Encl: A/a

Thyrocare Technologies Limited

 D-37/1, TTC MIDC, Turbhe, Navi Mumbai- 400 703, India  022- 3090 0000

 enquiry@thyrocare.com  www.thyrocare.com

(CIN : L85110MH2000PLC123882)

Annexure-1

Disclosure under sub-para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (LODR) Regulations, 2015 read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/ 0155 dated November 11, 2024

Change in Senior Management Personnel

1.	Name & Designation	Mr. Rajdeep Panwar – Chief Commercial Officer
2.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment
3.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Date of Appointment: January 05, 2026 Term of Appointment: As per the applicable Human Resources policies of the Company relating to superannuation
4.	Brief Profile (in case of appointment)	<p>Mr. Rajdeep Panwar is a senior healthcare and diagnostics industry professional with over 21 years of experience, having led large-scale diagnostic networks, laboratory operations and commercial functions across reputed healthcare organisations.</p> <p>He most recently served as Director – GHL Pharma & Diagnostics Limited (Medanta Labs), where he led the establishment and expansion of laboratory and pharmacy business verticals across North India.</p> <p>His prior experience includes leadership roles at Apollo Diagnostics, Dr. Lal PathLabs, Ortho Clinical Diagnostics (Johnson & Johnson Group), Quest Diagnostics India Private Limited, Sitaram Bhartia Institute of Science & Research and Pathnet India Private Limited.</p> <p>Mr. Panwar has extensive experience in P&L management, laboratory network expansion, business launches, digital diagnostics initiatives, NABL/CAP accreditation, LIMS integration and large-scale team leadership, and has played a key role in scaling diagnostic operations across metro and non-metro markets.</p> <p>He holds an M.Sc. in Biochemistry, B.Sc. in Medical Laboratory Technology, a Diploma in Medical Laboratory Technology, and is trained as an Internal Auditor for NABL ISO 15189.</p>
5.	Disclosure of relationships between directors (in case of appointment of a Director)	Not Applicable